Plain-English translation of NCT06440902 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study follows people with advanced colorectal cancer that started with a specific genetic mutation (called RAS). Researchers will take blood samples over time to see if the cancer's genetics change during your treatment. If the cancer does change in a particular way, it may open the door to a different type of therapy (called anti-EGFR therapy) that could work better for you.
Sometimes advanced colorectal cancer changes genetically during treatment, which could mean different medications become an option. This study wants to understand how often this happens and whether simple blood tests can reliably detect these changes to help doctors choose your next treatment.
You likely qualify if…
You likely don't qualify if…
After you join the study, you will receive standard treatment for your cancer as usual. When imaging scans show your cancer is growing, researchers will draw a blood sample to analyze it for genetic changes. If the genetic change they're looking for is detected, your doctor will discuss whether a different medication (anti-EGFR therapy) might be right for you next. The study involves regular visits for treatment and blood draws, but no experimental drugs are given to most participants—you're being monitored and guided through the blood test results.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China